

Added-Value Licensing Licensing-in on Gene Editing



THE SITUATION

Our client, a leading biotech company, sought to identify **CRISPR-Cas systems** utilizing Cas enzymes as alternatives to Cas9. To navigate the **complex patent landscape**, the client aimed to pinpoint **lower-risk patent portfolios** covering these alternative systems.

Achieving this goal required **in-depth technological insights**, combining a **detailed patent analysis** with the internationally recognized expertise of our CRISPR patent analysts.

OUR APPROACH

As a global leader in **CRISPR patent analytics**, SCBT-Centredoc leveraged its **proprietary RAPID platform**, which is updated monthly and includes over 22,000 patent families and 500 licensing announcements. This database, manually categorized across multiple technological breakdown and subcategories, enabled us to conduct a precise evaluation.

To refine our analysis, we performed supplementary **patent searches based on biological sequences**, ensuring the most accurate and relevant insights. Additionally, a **comprehensive legal and technological assessment** of selected patent portfolios helped identify their strengths and potential risks.

RESULTS & BENEFITS

- We identified **five key players** with **strong CRISPR patent portfolios** relevant to the client's strategic goals.
- For each player, we created a **detailed ID card** containing essential insights, including **licensing announcements and other business-critical updates**.
- Our final report included **strategic and technological recommendations**, helping the client make informed decisions.

Within months, our client successfully signed a **licensing-in agreement** with one of the identified CRISPR players. We also identified a **direct competitor** operating in the same niche, enabling the client to closely monitor their activities.

CONTACT US :



biotech@scbt.ch